Earlier today Pfizer stock was halted by the New York Stock Exchange. The reason: A Virginia court had invalidated the patent on the company’s drug Celebrex, which is expected to generate $2.1 billion in annual sales in 2014. In the worst case, generics of Celebrex could be available starting May 30, says Mark Schoenebaum at ISI Group, dropping earnings per share by $0.12 cents.
Hey, check out all the research scientist jobs. Post your resume today!
